Close Menu

Just Say No

A special committee of Genentech's board asks the company's investors to reject Roche's hostile bid, reports the Wall Street Journal. Genentech says that the hostile Roche offer, at $86.50 a share, is "inadequate and not in the best interest of shareholders" and undervalues Genentech's financial outlook, its history of developing new medicines, and its product pipeline. Roche responded to the committee's recommendation by saying Roche has made its case and it is now up to the investors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.